Unknown

Dataset Information

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.


ABSTRACT:

Background

Budesonide foam, a rectally administered, second-generation corticosteroid with extensive hepatic first-pass metabolism, is efficacious for the treatment of mild-to-moderate ulcerative proctitis and ulcerative proctosigmoiditis.

Aim

The aim of this study was to comprehensively assess the safety and pharmacokinetic profile of budesonide foam.

Methods

Data from five phase III studies were pooled to further evaluate safety, including an open-label study (once-daily treatment for 8 weeks), an active-comparator study (once-daily treatment for 4 weeks), and two placebo-controlled studies and an open-label extension study (twice-daily treatment for 2 weeks, then once daily for 4 weeks). Data from the placebo-controlled studies and two phase I studies (i.e., patien

SUBMITTER: Rubin DT 

PROVIDER: S-EPMC4621699 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature